Skip to main content
. 2021 Dec 24;11:760703. doi: 10.3389/fonc.2021.760703

Figure 1.

Figure 1

Chest CT images throughout the disease course. (A) Initial evaluation showed enlarged mediastinal lymph node. (B) Partial response (PR) after docetaxel-cisplatin. (C) Progressive disease after four cycles of docetaxel-cisplatin. (D) PR after afatinib. (E) Progressive disease after 2 months of afatinib. (F) Hyperprogressive disease after one cycle of pembrolizumab. PD-L1 expression before (G) and after (H) pembrolizumab monotherapy.